New and Emerging Targeted Therapies for Advanced Breast Cancer
In the United States, breast cancer is among the most frequently diagnosed cancers in women. Breast cancer is classified into four major subtypes: human epidermal growth factor receptor 2 (HER2), Luminal-A, Luminal-B, and Basal-like or triple-negative, based on histopathological criteria including t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/4/2288 |
| _version_ | 1797479258365362176 |
|---|---|
| author | Kristie H. Lau Alexandra M. Tan Yihui Shi |
| author_facet | Kristie H. Lau Alexandra M. Tan Yihui Shi |
| author_sort | Kristie H. Lau |
| collection | DOAJ |
| description | In the United States, breast cancer is among the most frequently diagnosed cancers in women. Breast cancer is classified into four major subtypes: human epidermal growth factor receptor 2 (HER2), Luminal-A, Luminal-B, and Basal-like or triple-negative, based on histopathological criteria including the expression of hormone receptors (estrogen receptor and/or progesterone receptor) and/or HER2. Primary breast cancer treatments can include surgery, radiation therapy, systemic chemotherapy, endocrine therapy, and/or targeted therapy. Endocrine therapy has been shown to be effective in hormone receptor-positive breast cancers and is a common choice for adjuvant therapy. However, due to the aggressive nature of triple-negative breast cancer, targeted therapy is becoming a noteworthy area of research in the search for non-endocrine-targets in breast cancer. In addition to HER2-targeted therapy, other emerging therapies include immunotherapy and targeted therapy against critical checkpoints and/or pathways in cell growth. This review summarizes novel targeted breast cancer treatments and explores the possible implications of combination therapy. |
| first_indexed | 2024-03-09T21:44:14Z |
| format | Article |
| id | doaj.art-9ffaa646f9a744dbbf3a34f27a5e8709 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T21:44:14Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-9ffaa646f9a744dbbf3a34f27a5e87092023-11-23T20:23:04ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-02-01234228810.3390/ijms23042288New and Emerging Targeted Therapies for Advanced Breast CancerKristie H. Lau0Alexandra M. Tan1Yihui Shi2Department of Basic Science, College of Medicine, California Northstate University, Elk Grove, CA 95757, USADepartment of Basic Science, College of Medicine, California Northstate University, Elk Grove, CA 95757, USADepartment of Basic Science, College of Medicine, California Northstate University, Elk Grove, CA 95757, USAIn the United States, breast cancer is among the most frequently diagnosed cancers in women. Breast cancer is classified into four major subtypes: human epidermal growth factor receptor 2 (HER2), Luminal-A, Luminal-B, and Basal-like or triple-negative, based on histopathological criteria including the expression of hormone receptors (estrogen receptor and/or progesterone receptor) and/or HER2. Primary breast cancer treatments can include surgery, radiation therapy, systemic chemotherapy, endocrine therapy, and/or targeted therapy. Endocrine therapy has been shown to be effective in hormone receptor-positive breast cancers and is a common choice for adjuvant therapy. However, due to the aggressive nature of triple-negative breast cancer, targeted therapy is becoming a noteworthy area of research in the search for non-endocrine-targets in breast cancer. In addition to HER2-targeted therapy, other emerging therapies include immunotherapy and targeted therapy against critical checkpoints and/or pathways in cell growth. This review summarizes novel targeted breast cancer treatments and explores the possible implications of combination therapy.https://www.mdpi.com/1422-0067/23/4/2288breast cancerbreast cancer treatmentHER2targeted therapyemerging therapies |
| spellingShingle | Kristie H. Lau Alexandra M. Tan Yihui Shi New and Emerging Targeted Therapies for Advanced Breast Cancer International Journal of Molecular Sciences breast cancer breast cancer treatment HER2 targeted therapy emerging therapies |
| title | New and Emerging Targeted Therapies for Advanced Breast Cancer |
| title_full | New and Emerging Targeted Therapies for Advanced Breast Cancer |
| title_fullStr | New and Emerging Targeted Therapies for Advanced Breast Cancer |
| title_full_unstemmed | New and Emerging Targeted Therapies for Advanced Breast Cancer |
| title_short | New and Emerging Targeted Therapies for Advanced Breast Cancer |
| title_sort | new and emerging targeted therapies for advanced breast cancer |
| topic | breast cancer breast cancer treatment HER2 targeted therapy emerging therapies |
| url | https://www.mdpi.com/1422-0067/23/4/2288 |
| work_keys_str_mv | AT kristiehlau newandemergingtargetedtherapiesforadvancedbreastcancer AT alexandramtan newandemergingtargetedtherapiesforadvancedbreastcancer AT yihuishi newandemergingtargetedtherapiesforadvancedbreastcancer |